GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Cash, Cash Equivalents, Marketable Securities

Q32 Bio (Q32 Bio) Cash, Cash Equivalents, Marketable Securities : $135.31 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Cash, Cash Equivalents, Marketable Securities?

Q32 Bio's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($36.26 Mil) to Dec. 2023 ($25.62 Mil) but then increased from Dec. 2023 ($25.62 Mil) to Mar. 2024 ($135.31 Mil).

Q32 Bio's annual cash, cash equivalents, marketable securities increased from Dec. 2021 ($32.25 Mil) to Dec. 2022 ($43.89 Mil) but then declined from Dec. 2022 ($43.89 Mil) to Dec. 2023 ($25.62 Mil).


Q32 Bio Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Q32 Bio's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Cash, Cash Equivalents, Marketable Securities Chart

Q32 Bio Annual Data
Trend Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
32.25 43.89 25.62

Q32 Bio Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial 43.89 - 36.26 25.62 135.31

Q32 Bio Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Q32 Bio  (NAS:QTTB) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Q32 Bio Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Q32 Bio (Q32 Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Cash, Cash Equivalents, Marketable Securities
Comparable Companies
Traded in Other Exchanges
N/A
Address
830 Winter Street, Waltham, MA, USA, 02451
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus